World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 26 September 2016
Main ID:  NCT02722694
Date of registration: 10/03/2016
Prospective Registration: Yes
Primary sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Public title: A Phase 3 Study of Abatacept in Chinese Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Scientific title: A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Abatacept 125mg Administered Subcutaneously in Chinese Subjects With Active Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate
Date of first enrolment: August 2016
Target sample size: 360
Recruitment status: Recruiting
URL:  https://clinicaltrials.gov/show/NCT02722694
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment  
Phase:  Phase 3
Countries of recruitment
China
Contacts
Name:     Xiaofeng Zeng
Address: 
Telephone: 86-10-69158793
Email: xiaofeng.zeng@cstar.org.cn
Affiliation: 
Name:     Xiaofeng Zeng
Address: 
Telephone: 86-10-69158793
Email: xiaofeng.zeng@cstar.org.cn
Affiliation: 
Key inclusion & exclusion criteria

Inclusion Criteria:

- Subjects are willing to participate in this study and sign informed consent;

- Subjects must meet the criteria of the America Rheumatism Association (1987) for the
diagnosis of rheumatoid arthritis and ACR (1991) functional classes I, II or III;

- Subjects must have had Rheumatoid Arthritis for at least 6 months;

- Subjects who have inadequately response to MTX, must have been taking methotrexate
for at least 3 months with minimal dose of 10 mg weekly, and at a stable dose for at
least 28 days prior to randomization (Day 1). Methotrexate weekly dose as low as 7.5
mg is permitted for subjects who cannot tolerate higher dose, and the intolerance of
higher dose than 7.5mg weekly should be well documented;

- Subjects must have the following disease activity at randomization:

1. 6 or more swollen joints(66 joint count);

2. 8 or more tender joints(68 joint count); and

3. C reactive protein (hsCRP) > 3 mg/L (based on the result of screening visit) or
ESR = 28mm/hr;

- All DMARDs (except methotrexate) should be discontinued for at least 28 days prior to
study randomization (Day 1), Leflunomide must have been discontinued =8 weeks (the
subject can be washed-out with cholestyramine according to label recommendations);

- Oral corticosteroid treatment must have been reduced to the prednisone = 10 mg daily
or equivalent for 28 days,and stabilized for at least 25 out of 28 days prior to
randomization (Day 1). Corticosteroid administered by intra-articular (IA) or
intramuscular (IM) will not be allowed 28 days prior to randomization (Day 1);

- Stable NSAIDs are permitted;

- Male and female subject =18 years old;

- Women of childbearing potential (WOCBP) must have a negative pregnancy test within 24
hours prior to the start of study medication;

Exclusion Criteria:

- WOCBP and male patients of childbearing potential who are unwilling or unable to use
an acceptable method to avoid pregnancy for the entire study period and for up to 10
weeks after the last dose of study medication;

- Women who are pregnant or breast-feeding;

- Women with a positive pregnancy test on enrollment or prior to study drug
administration;

- Subjects meet diagnosis criteria of other rheumatoid disease (e.g., systemic lupus
erythematosus);

- Subjects with active vasculitis of the major organ systems (except for subcutaneous
rheumatoid nodules);

- Current symptoms of severe, progressive or uncontrolled diseases of renal, hepatic,
hematological, gastrointestinal, pulmonary, cardiac, neurological, or cerebral.
Concomitant medical conditions that, in the opinion of the investigator, might place
the subject at unacceptable risk for participation in this study;

- Subjects with a history of cancer within the last five years (other than non-melanoma
skin cell cancers cured by local resection). Existing non-melanoma skin cell cancers
must be removed prior to dosing. Subjects with carcinoma in situ, treated with
definitive surgical intervention, are allowed;

- Subjects who have a history of drug or alcohol abuse;

- Subjects with any serious bacterial infection within the last 3 months (such as
pneumonia or pyelonephritis, unless treated and resolved with antibiotics);

- Subjects with serious, chronic or recurrent bacterial infection (such as recurrent
pneumonia and chronic bronchiectasis);

- Subjects at risk for tuberculosis (TB), Specially, :

1. Having evidences of clinical, imaging or lab test of current active or latent
pulmonary tuberculosis;

2. Having active pulmonary tuberculosis during the past 3 years, even if had
treated;

3. Having history of active pulmonary tuberculosis more than 3 years ago, unless
the appropriate duration and types of anti-tuberculosis drug is well documented;

- Subjects with herpes zoster that resolved less than 2 months before enrollment;

- Subjects with evidence (as assessed by the Investigator) of active or latent
bacterial or viral infections at the time of potential enrollment, including subjects
with evidence of Human Immunodeficiency Virus (HIV) infection;

- Subjects are impaired, incapacitated, or incapable of completing study related
assessment;

- Hepatitis-B surface antigen-positive subjects.

- Hepatitis C antibody-positive subjects

- HIV antibody-positive subjects

- Subjects with any of the following laboratory values:

1. Hgb < 85 g/L

2. white blood cell count < 3,000/mm3(3×10^9/L)

3. Platelets < 100,000/mm3(100×10^9/L);

4. Creatinine clearance < 40 mL/min;

5. Serum glutamic pyruvic transaminase (GPT or ALT) or glutamic oxaloacetic
transaminase (GOT or AST)>2 times upper limit of normal;

6. Any other laboratory test results that, in the opinion of the Investigator,
might place the subject at unacceptable risk for participation in this study;

- Subjects who have received treatment with rituximab at any time;

- Subjects who had prior exposure to abatacept or CTLA4-Ig;

- Subjects who have received treatment with any investigational drug within 28 days (or
less than 5 terminal half-lives of elimination) (whichever is longer);

- Subjects currently (when signing informed consent) treated with an anti-tumor
necrosis factor (TNF) therapy, such as adalimumab and infliximab (within 8 weeks of
the last dose), or etanercept (within 4 weeks of the last dose);

- Subjects who discontinued an approved biologic RA therapy due to lack of efficacy in
the past;

- Subjects exposed to multiple (>3) approved biologic RA therapies in the past;

- Subjects currently treated with anakinra unless a minimum 4-week wash-out period has
been completed before Day 1;

- Subjects who received prior treatment with any investigational biologic not currently
approved;

- Subjects who had been exposed to any approved biologic within 4 weeks or 5
half-lives, whichever was longer;

- Subjects are (when signing informed consent)receiving an investigational biologic RA
therapy or an approved biologic RA therapy;

- Subjects who have received any active vaccine within 3 months of the first dose of
the study medication or plan to receive active vaccine during the study;

- Prisoners or subjects who are involuntarily incarcerated;

- Subjects who



Age minimum: 18 Years
Age maximum: N/A
Gender: Both
Health Condition(s) or Problem(s) studied
Rheumatoid Arthritis (RA)
Intervention(s)
Drug: Methotrexate
Drug: Subcutaneous(SC) Abatacept
Other: Placebo
Primary Outcome(s)
The proportion of subjects meeting ACR 20 at 24 weeks (Day 169) [Time Frame: Day 169]
Secondary Outcome(s)
The proportion of subject meeting Health Assessment Questionnaire Disability Index (HAQ-DI) improvement at 24 weeks (Day 169) [Time Frame: Day 169]
The proportion of subjects meeting ACR 50 at 24 weeks (Day 169) [Time Frame: Day 169]
The proportion of subjects meeting ACR 70 at 24 weeks (Day 169) [Time Frame: Day 169]
Secondary ID(s)
SIM-126-III
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Bristol-Myers Squibb
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history